Beyond access: how wealth and race shape GLP-1 treatment outcomes in diabetes and weight loss
At Forian, we believe that analyzing patient cohorts aligned not only with general healthcare trends but also with how treatments are represented in popular culture is important. This approach helps gauge public perceptions and misconceptions, ensuring that scientific advancements are communicated effectively and can be embraced or critically assessed by the broader community.
In this Guest Column, Mike Sicilia, RWE Data Scientist, Forian, describes how data analytics capabilities have uncovered significant patterns in the accessibility and effectiveness of Glucagon-like peptide-1 (GLP-1) therapies, shedding light on how socioeconomic factors such as race and wealth impact patient outcomes.
Sections:
- Real-world data indicates socioeconomic disparities in GLP-1 therapy
- Beyond diabetes: how wealth and race influence GLP-1 usage
- The cost of care: pre-GLP-1 medication spending and insulin usage among diabetes patients
- Wealth versus weight: how BMI varies by and race in non-diabetic GLP-1 users
- Providing equitable access across all socioeconomic groups
Click the button below to continue reading.
READ THE FULL GUEST COLUMN HERE
Author
Michael Sicilia
RWD Data Scientist, Forian, Inc.
Michael Sicilia is a RWE Data Scientist at Forian, Inc., where he designs and conducts real-world evidence studies. Prior to joining Forian in June 2024, Michael was at EVERSANA where he implemented complex outcome, economic, burden-of-illness, and machine learning analyses on rare disease patient populations. In total, he has over 5 years of experience in the real-world data/evidence space and holds a bachelor’s degree in Computer Science.
Sponsorship for this Guest Column was provided by Forian.